MMCM
PDLI

Murphy & Mullick Capital Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Murphy & Mullick Capital Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
100
– – ﹤0.01% 799
2025
Q4 		$0 Hold
100
– – ﹤0.01% 838
2025
Q3 		$0 Hold
100
– – ﹤0.01% 690
2025
Q2 		$0 Hold
100
– – ﹤0.01% 712
2025
Q1 		$0 Hold
100
– – ﹤0.01% 697
2024
Q4 		$0 Buy
+100
New – ﹤0.01% 670

Other funds holding PDLI

DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

Murphy & Mullick Capital Management's PDLI Position: Q1 2026 in Review

Murphy & Mullick Capital Management held its PDL BioPharma, Inc. (PDLI) position steady in Q1 2026 at 100 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #799.

Murphy & Mullick Capital Management first reported a position in PDLI in Q4 2024 and has held it in 6 quarters since. 6 funds tracked by Wall St. Rank hold PDLI as of Q1 2026.

  • Murphy & Mullick Capital Management held 100 shares of PDL BioPharma, Inc. worth $0 as of Q1 2026.
  • Murphy & Mullick Capital Management left its PDL BioPharma, Inc. share count unchanged in Q1 2026.
  • PDL BioPharma, Inc. made up ﹤0.01% of Murphy & Mullick Capital Management's portfolio in Q1 2026, its #799 holding.
  • Murphy & Mullick Capital Management first reported a position in PDL BioPharma, Inc. in Q4 2024 and has held it in 6 quarters since.
  • 6 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2026.

Based on Murphy & Mullick Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.